

Practitioner's Docket No. MPI00-212CP1CN1RCEMUSSN: 10/644,671RECEIVED
CENTRAL FAX CENTER

REMARKS / ARGUMENTS

MAR 06 2008

Applicants have amended claim 24. Support for this amendment can be found throughout the specification and claims as filed. No new matter has been added by way of amendment. Claims 24-33 will be pending upon entry of this amendment.

**Rejection of Claims 24-33 under 35 USC §112, First Paragraph (Enablement),
Should Be Withdrawn**

Claims 24-33 were rejected under 35 USC §112, first paragraph, as failing to comply with the enablement requirement. The Examiner argued that the claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention. The Examiner asserted that the specification does not enable one of skill in the art to practice the invention without undue experimentation.

Specifically, the Examiner stated that the "one of skill in the art is not enabled to make and use the claimed polypeptide with the recited functional properties, and hence to practice the claimed methods."

Applicants traverse the rejection. However, solely in an effort to expedite prosecution, Applicants have amended base claim 24 to recite methods using polypeptides which comprise SEQ ID NO:4, or which are encoded by a nucleic acids which comprise SEQ ID NO:3 or SEQ ID NO:21, or which are encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number PTA-2085. Thus, Applicants submit that the polypeptides used in the claimed methods as amended are sufficiently described in the specification so as to enable one of ordinary skill in the art to practice the claimed methods.

Applicants respectfully request reconsideration and withdrawal of the rejection under 35 USC §112, first paragraph.

(Page 4 of 5)

Practitioner's Docket No. MPI00-212CP1CN1RCEM

MAR 06 2008

USSN: 10/644,671**CONCLUSION**

In view of the remarks herein, Applicants respectfully submit that the rejection presented by the Examiner is now overcome and that this application is in condition for allowance. If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned.

This paper is being filed timely as a request for a two month extension of time is filed concurrently herewith. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

March 6, 2008

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By


Jonathan K. Hamm, Ph.D.

Registration No. 59,608

40 Landsdowne Street

Cambridge, MA 02139

Telephone -- (617) 679-7166

Facsimile -- (617) 551-8820

(Page 5 of 5)